公开(公告)号：US20250163104A1

公开(公告)日：2025-05-22

申请号：US18715382

申请日：2022-12-02

Applicant: Bristol-Myers Squibb Company

Inventor： Jennifer X. QIAO ,  Michael A. POSS ,  Martin Patrick ALLEN ,  Claudio MAPELLI ,  Claude A. QUESNELLE ,  David R. TORTOLANI ,  Tammy C. WANG ,  Tao WANG ,  Yong ZHANG ,  Yunhui ZHANG ,  Zhongxing ZHANG

IPC: C07K7/56 ,  A61K38/12

Abstract: In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-I and are capable of inhibiting the interaction of PD-I with PD-LI. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.

公开(公告)号：US20230242585A1

公开(公告)日：2023-08-03

申请号：US17998137

申请日：2021-05-07

Applicant: Bristol-Myers Squibb Company

Inventor： Tao WANG ,  Paul Michael SCOLA ,  Zhongxing ZHANG

IPC: C07K7/54

CPC classification number: C07K7/54 ,  A61K38/00

Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PDL 1 and PD-L 1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

公开(公告)号：US20230183292A1

公开(公告)日：2023-06-15

申请号：US17906519

申请日：2021-03-16

Applicant: Bristol-Myers Squibb Company

Inventor： Tao WANG ,  Zhongzing Zhang

IPC: C07K7/56 ,  A61K47/55

CPC classification number: C07K7/56 ,  A61K47/55 ,  A61K38/00

Abstract: In accordance with the present disclosure, compounds have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.

公开(公告)号：US20220251141A1

公开(公告)日：2022-08-11

申请号：US17612915

申请日：2020-05-21

Applicant: Bristol-Myers Squibb Company

Inventor： Tao WANG ,  Li-Qiang SUN ,  Zhaoxing MENG ,  Paul SCOLA

IPC: C07K7/52

Abstract: In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.

公开(公告)号：US20230374073A1

公开(公告)日：2023-11-23

申请号：US18030598

申请日：2021-10-08

Applicant: Bristol-Myers Squibb Company

Inventor： Tao WANG

IPC: C07K7/56

CPC classification number: C07K7/56 ,  A61K38/00

Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

公开(公告)号：US20220389061A1

公开(公告)日：2022-12-08

申请号：US17772343

申请日：2020-10-29

Applicant: Bristol-Myers Squibb Company

Inventor： Tao WANG ,  Paul Michael SCOLA ,  Zhongxing ZHANG

IPC: C07K7/54 ,  A61P31/00 ,  A61P35/00

Abstract: In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.